glp-1 agonist drugs oral new glp 1 In the ATTAIN-1 phase 3, randomized trial, the use of orforglipron GLP-1 Medications for Weight Loss:

Mounjaro is FDA-approved to treat type 2 diabetes alongside diet and exercise

SAN DIEGO and DALLAS, June 17, 2025 /PRNewswire/ -- 9amHealth, a leader in complete cardiometabolic care, and Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs), today announced a collaboration that will make obesity medications more affordable and accessible to employers nationwide

New patients without insurance can use a limited-time offer and pay $199 per month for the first two months

We forecast one to two GLP-1 launches annually starting in 2026, with the first oral entrant expected by 2027

But as more patients explore or discontinue these medications, functional and integrative medicine providers have a growing opportunity to offer complementary or alternative strategies that support similar metabolic pathwaysoften with fewer side effects

Dulaglutide protects mice against diabetic sarcopenia-mediated muscle injury by inhibiting inflammation and regulating the differentiation of myoblasts